Primary Sjögren's syndrome

Best Practice and Research: Clinical Rheumatology

Volumn 30, Issue 1, 2016, Pages 189-220

  Rischmueller, Maureen ^a,b   Tieu, Joanna ^a   Lester, Susan ^a,b  

^a QUEEN ELIZABETH HOSPITAL   (Australia)

^b UNIVERSITY OF ADELAIDE   (Australia)

Author keywords

ESSDAI; ESSPRI; Labial biopsy; Primary Sj gren's syndrome; Rituximab

Indexed keywords

AUTOANTIBODY; LA ANTIBODY; RO ANTIBODY;

ADAPTIVE IMMUNITY; ARTHROPATHY; B LYMPHOCYTE; CLINICAL FEATURE; CLINICAL PRACTICE; COHORT ANALYSIS; CONGENITAL HEART BLOCK; CRYOGLOBULINEMIA; CYTOPENIA; DISEASE CLASSIFICATION; DRY EYE; DRY SKIN; EPIGENETICS; FATIGUE; HISTOPATHOLOGY; HUMAN; INCIDENCE; KIDNEY DISEASE; LUNG DISEASE; LUPUS VULGARIS; MORBIDITY; MORTALITY; NEUROLOGIC DISEASE; NONHODGKIN LYMPHOMA; OUTCOME ASSESSMENT; PAIN; PAROTID ENLARGEMENT; PATHOGENESIS; PERIPHERAL NERVOUS SYSTEM; PREVALENCE; PRIORITY JOURNAL; RAYNAUD PHENOMENON; REVIEW; SALIVARY GLAND BIOPSY; SALIVARY GLAND DISEASE; SALIVARY GLAND SCINTISCANNING; SIALOGRAPHY; SJOEGREN SYNDROME; SKIN DEFECT; SKIN DISEASE; URETHRA DISEASE; VASCULITIS; XEROSTOMIA; AUTOIMMUNITY; IMMUNOLOGY; PATHOLOGY; SALIVARY GLAND;

AUTOANTIBODIES; AUTOIMMUNITY; HUMANS; SALIVARY GLANDS; SJOGREN'S SYNDROME;

EID: 84967019965     PISSN: 15216942     EISSN: 15321770     Source Type: Journal    
DOI: 10.1016/j.berh.2016.04.003     Document Type: Review

References (141)

1. *[1] Brito-Zeron, P., Theander, E., Baldini, C., et al. Early diagnosis of primary Sjogren's syndrome: EULAR-SS task force clinical recommendations. Expert Rev Clin Immunol, 2015, 1–20.
2. [2] van Nimwegen, J.F., Arends, S., van Zuiden, G.S., et al. The impact of primary Sjogren's syndrome on female sexual function. Rheumatol Oxf 54:7 (2015), 1286–1293.
3. [3] Ramos-Casals, M., Brito-Zeron, P., Solans, R., et al. Systemic involvement in primary Sjogren's syndrome evaluated by the EULAR-SS disease activity index: analysis of 921 Spanish patients (GEAS-SS Registry). Rheumatol Oxf 53:2 (2014), 321–331.
4. [4] Kulkarni, K., Unusual presentation of Sjogren syndrome. South Med J 98:12 (2005), 1210–1211.
5. [5] Yamamoto, M., Takahashi, H., Sugai, S., Imai, K., Clinical and pathological characteristics of Mikulicz's disease (IgG4-related plasmacytic exocrinopathy). Autoimmun Rev 4:4 (2005), 195–200.
6. [6] Baszis, K., Toib, D., Cooper, M., et al. Recurrent parotitis as a presentation of primary pediatric Sjogren syndrome. Pediatrics 129:1 (2012), e179–182.
7. [7] Civilibal, M., Canpolat, N., Yurt, A., et al. A child with primary Sjogren syndrome and a review of the literature. Clin Pediatr (Phila) 46:8 (2007), 738–742.
8. [8] Abrol, E., Gonzalez-Pulido, C., Praena-Fernandez, J.M., Isenberg, D.A., A retrospective study of long-term outcomes in 152 patients with primary Sjogren's syndrome: 25-year experience. Clin Med 14:2 (2014), 157–164.
9. Seror, R., Ravaud, P., Bowman, S.J., et al. EULAR Sjogren's syndrome disease activity index: development of a consensus systemic disease activity index for primary Sjogren's syndrome. Ann Rheum Dis 69:6 (2010), 1103–1109.
10. [10] Baldini, C., Pepe, P., Quartuccio, L., et al. Primary Sjogren's syndrome as a multi-organ disease: impact of the serological profile on the clinical presentation of the disease in a large cohort of Italian patients. Rheumatol Oxf 53:5 (2014), 839–844.
11. Luciano, N., Valentini, V., Calabro, A., et al. One year in review 2015: Sjogren's syndrome. Clin Exp Rheumatol 33:2 (2015), 259–271.
12. [12] Ramos-Casals, M., Brito-Zeron, P., Siso-Almirall, A., Bosch, X., Primary Sjogren syndrome. BMJ, 344, 2012, e3821.
13. [13] Segal, B.M., Pogatchnik, B., Holker, E., et al. Primary Sjogren's syndrome: cognitive symptoms, mood, and cognitive performance. Acta Neurol Scand 125:4 (2012), 272–278.
14. [14] Theander, L., Strombeck, B., Mandl, T., Theander, E., Sleepiness or fatigue? Can we detect treatable causes of tiredness in primary Sjogren's syndrome?. Rheumatol Oxf 49:6 (2010), 1177–1183.
15. [15] Westhoff, G., Dorner, T., Zink, A., Fatigue and depression predict physician visits and work disability in women with primary Sjogren's syndrome: results from a cohort study. Rheumatol Oxf 51:2 (2012), 262–269.
16. [16] Cai, F.Z., Lester, S., Lu, T., et al. Mild autonomic dysfunction in primary Sjogren's syndrome: a controlled study. Arthritis Res Ther, 10(2), 2008, R31.
17. [17] Newton, J.L., Frith, J., Powell, D., et al. Autonomic symptoms are common and are associated with overall symptom burden and disease activity in primary Sjogren's syndrome. Ann Rheum Dis 71:12 (2012), 1973–1979.
18. [18] Seror, R., Ravaud, P., Mariette, X., et al. EULAR Sjogren's Syndrome Patient Reported Index (ESSPRI): development of a consensus patient index for primary Sjogren's syndrome. Ann Rheum Dis 70:6 (2011), 968–972.
19. [19] Hilditch, C.J., McEvoy, R.D., George, K.E., et al. Upper airway surface tension but not upper airway collapsibility is elevated in primary Sjogren's syndrome. Sleep 31:3 (2008), 367–374.
20. [20] Usmani, Z.A., Hlavac, M., Rischmueller, M., et al. Sleep disordered breathing in patients with primary Sjogren's syndrome: a group controlled study. Sleep Med 13:8 (2012), 1066–1070.
21. [21] Segal, B.M., Pogatchnik, B., Henn, L., et al. Pain severity and neuropathic pain symptoms in primary Sjogren's syndrome: a comparison study of seropositive and seronegative Sjogren's syndrome patients. Arthritis Care Res Hob 65:8 (2013), 1291–1298.
22. [22] ter Borg, E.J., Kelder, J.C., Lower prevalence of extra-glandular manifestations and anti-SSB antibodies in patients with primary Sjogren's syndrome and widespread pain: evidence for a relatively benign subset. Clin Exp Rheumatol 32:3 (2014), 349–353.
23. Ramos-Casals, M., Brito-Zeron, P., Seror, R., et al. Characterization of systemic disease in primary Sjogren's syndrome: EULAR-SS task force recommendations for articular, cutaneous, pulmonary and renal involvements. Rheumatol Oxf 54:12 (2015), 2230–2238.
24. [24] Ramos-Casals, M., Anaya, J.M., Garcia-Carrasco, M., et al. Cutaneous vasculitis in primary Sjogren syndrome: classification and clinical significance of 52 patients. Medicine 83:2 (2004), 96–106.
25. [25] Stojan, G., Baer, A.N., Danoff, S.K., Pulmonary manifestations of Sjogren's syndrome. Curr Allergy Asthma Rep 13:4 (2013), 354–360.
26. [26] Pavlakis, P.P., Alexopoulos, H., Kosmidis, M.L., et al. Peripheral neuropathies in Sjogren's syndrome: a critical update on clinical features and pathogenetic mechanisms. J Autoimmun 39:1–2 (2012), 27–33.
27. [27] Sene, D., Cacoub, P., Authier, F.J., et al. Sjogren syndrome-associated small fiber neuropathy: characterization from a prospective series of 40 cases. Medicine 92:5 (2013), e10–e18.
28. [28] Akasbi, M., Berenguer, J., Saiz, A., et al. White matter abnormalities in primary Sjogren syndrome. QJM 105:5 (2012), 433–443.
29. [29] Evans, R., Zdebik, A., Ciurtin, C., Walsh, S.B., Renal involvement in primary Sjogren's syndrome. Rheumatol Oxf 54:9 (2015), 1541–1548.
30. [30] Walker, J., Gordon, T., Lester, S., et al. Increased severity of lower urinary tract symptoms and daytime somnolence in primary Sjogren's syndrome. J Rheumatol 30:11 (2003), 2406–2412.
31. [31] Ramos-Casals, M., Daniels, T., Fox, R.I., et al. Sjögren's syndrome. Stone, J.H., (eds.) A clinician's pearls and myths in rheumatology, 2009, Springer, New York.
32. [32] Schattner, A., Friedman, J., Klepfish, A., Thrombotic thrombocytopenic purpura as an initial presentation of primary Sjogren's syndrome. Clin Rheumatol 21:1 (2002), 57–59.
33. [33] Brito-Zeron, P., Izmirly, P.M., Ramos-Casals, M., et al. The clinical spectrum of autoimmune congenital heart block. Nat Rev Rheumatol 11:5 (2015), 301–312.
34. [34] Rivera, T.L., Izmirly, P.M., Birnbaum, B.K., et al. Disease progression in mothers of children enrolled in the research registry for neonatal lupus. Ann Rheum Dis 68:6 (2009), 828–835.
35. [35] Levesque, K., Maltret, A., Hamidou, M., et al. French cohort study of 141 cases of autoimmune congenital heart block. 2012 ACR/ARHP annual meeting, 2012 San Diego, CA, USA. November 10–14: Arthritis Rheum;64(S10):Abstract: 1649.
36. [36] Liang, Y., Yang, Z., Qin, B., Zhong, R., Primary Sjogren's syndrome and malignancy risk: a systematic review and meta-analysis. Ann Rheum Dis 73:6 (2014), 1151–1156.
37. [37] Vajdic, C.M., Landgren, O., McMaster, M.L., et al. Medical history, lifestyle, family history, and occupational risk factors for lymphoplasmacytic lymphoma/Waldenstrom's macroglobulinemia: the InterLymph Non-Hodgkin Lymphoma Subtypes Project. J Natl Cancer Inst Monogr 2014:48 (2014), 87–97.
38. [38] Nocturne, G., Mariette, X., Sjogren syndrome-associated lymphomas: an update on pathogenesis and management. Br J Haematol 168:3 (2015), 317–327.
39. [39] Voulgarelis, M., Ziakas, P.D., Papageorgiou, A., et al. Prognosis and outcome of non-Hodgkin lymphoma in primary Sjogren syndrome. Medicine 91:1 (2012), 1–9.
40. [40] Papageorgiou, A., Ziogas, D.C., Mavragani, C.P., et al. Predicting the outcome of Sjogren's syndrome-associated non-hodgkin's lymphoma patients. PLoS One, 10(2), 2015, e0116189.
41. [41] Nishishinya, M.B., Pereda, C.A., Munoz-Fernandez, S., et al. Identification of lymphoma predictors in patients with primary Sjogren's syndrome: a systematic literature review and meta-analysis. Rheumatol Int 35:1 (2015), 17–26.
42. Theander, E., Vasaitis, L., Baecklund, E., et al. Lymphoid organisation in labial salivary gland biopsies is a possible predictor for the development of malignant lymphoma in primary Sjogren's syndrome. Ann Rheum Dis 70:8 (2011), 1363–1368.
43. [43] Nocturne, G., Tarn, J., Boudaoud, S., et al. Germline variation of TNFAIP3 in primary Sjogren's syndrome-associated lymphoma. Ann Rheum Dis 75:4 (2016), 780–783.
44. [44] Nezos, A., Papageorgiou, A., Fragoulis, G., et al. B-cell activating factor genetic variants in lymphomagenesis associated with primary Sjogren's syndrome. J Autoimmun 51 (2014), 89–98.
45. [45] Wang, S.S., Lu, Y., Rothman, N., et al. Variation in effects of non-Hodgkin lymphoma risk factors according to the human leukocyte antigen (HLA)-DRB1*01:01 allele and ancestral haplotype 8.1. PLoS One, 6(11), 2011, e26949.
46. [46] Tomi, A.L., Belkhir, R., Nocturne, G., et al. Monoclonal gammopathy and risk of lymphoma and multiple myeloma in patients with primary Sjogren's syndrome. Arthritis Rheumatol 68:5 (2016), 1245–1250.
47. [47] Weng, M.Y., Huang, Y.T., Liu, M.F., Lu, T.H., Incidence of cancer in a nationwide population cohort of 7852 patients with primary Sjogren's syndrome in Taiwan. Ann Rheum Dis 71:4 (2012), 524–527.
48. [48] Qin, B., Wang, J., Yang, Z., et al. Epidemiology of primary Sjogren's syndrome: a systematic review and meta-analysis. Ann Rheum Dis 74:11 (2015), 1983–1989.
49. [49] Alamanos, Y., Tsifetaki, N., Voulgari, P.V., et al. Epidemiology of primary Sjogren's syndrome in north-west Greece, 1982-2003. Rheumatol Oxf 45:2 (2006), 187–191.
50. [50] Pillemer, S.R., Matteson, E.L., Jacobsson, L.T., et al. Incidence of physician-diagnosed primary Sjogren syndrome in residents of Olmsted County, Minnesota. Mayo Clin Proc 76:6 (2001), 593–599.
51. [51] Weng, M.Y., Huang, Y.T., Liu, M.F., Lu, T.H., Incidence and mortality of treated primary Sjogren's syndrome in Taiwan: a population-based study. J Rheumatol 38:4 (2011), 706–708.
52. [52] Lendrem, D., Mitchell, S., McMeekin, P., et al. Health-related utility values of patients with primary Sjogren's syndrome and its predictors. Ann Rheum Dis 73:7 (2014), 1362–1368.
53. [53] Kotsis, K., Voulgari, P.V., Tsifetaki, N., et al. Illness perceptions and psychological distress associated with physical health-related quality of life in primary Sjogren's syndrome compared to systemic lupus erythematosus and rheumatoid arthritis. Rheumatol Int 34:12 (2014), 1671–1681.
54. [54] Callaghan, R., Prabu, A., Allan, R.B., et al. Direct healthcare costs and predictors of costs in patients with primary Sjogren's syndrome. Rheumatol Oxf 46:1 (2007), 105–111.
55. [55] Singh, A.G., Singh, S., Matteson, E.L., Rate, risk factors and causes of mortality in patients with Sjogren's syndrome: a systematic review and meta-analysis of cohort studies. Rheumatol Oxf 55:3 (2016), 450–460.
56. [56] Theander, E., Manthorpe, R., Jacobsson, L.T., Mortality and causes of death in primary Sjogren's syndrome: a prospective cohort study. Arthritis Rheum 50:4 (2004), 1262–1269.
57. [57] Shiboski, S.C., Shiboski, C.H., Criswell, L., et al. American College of Rheumatology classification criteria for Sjogren's syndrome: a data-driven, expert consensus approach in the Sjogren's International Collaborative Clinical Alliance cohort. Arthritis Care Res Hob 64:4 (2012), 475–487.
58. [58] Vitali, C., Bootsma, H., Bowman, S.J., et al. Classification criteria for Sjogren's syndrome: we actually need to definitively resolve the long debate on the issue. Ann Rheum Dis 72:4 (2013), 476–478.
59. [59] Nardi, N., Brito-Zeron, P., Ramos-Casals, M., et al. Circulating auto-antibodies against nuclear and non-nuclear antigens in primary Sjogren's syndrome: prevalence and clinical significance in 335 patients. Clin Rheumatol 25:3 (2006), 341–346.
60. [60] Patel, R., Shahane, A., The epidemiology of Sjogren's syndrome. Clin Epidemiol 6 (2014), 247–255.
61. [61] Gottenberg, J.E., Busson, M., Loiseau, P., et al. In primary Sjogren's syndrome, HLA class II is associated exclusively with autoantibody production and spreading of the autoimmune response. Arthritis Rheum 48:8 (2003), 2240–2245.
62. [62] Rischmueller, M., Lester, S., Chen, Z., et al. HLA class II phenotype controls diversification of the autoantibody response in primary Sjogren's syndrome (pSS). Clin Exp Immunol 111:2 (1998), 365–371.
63. [63] Tan, E.M., Antinuclear antibodies: diagnostic markers for autoimmune diseases and probes for cell biology. Adv Immunol 44 (1989), 93–151.
64. [64] Schulte-Pelkum, J., Fritzler, M., Mahler, M., Latest update on the Ro/SS-A autoantibody system. Autoimmun Rev 8:7 (2009), 632–637.
65. [65] Lester, S., Danda, D., Cavill, D., et al. Humoral immunity to Ro52 is not associated with the Ro52 9571 C/T polymorphism in Australian patients with primary Sjogren's syndrome. Arthritis Rheum 48:11 (2003), 3293–3294.
66. [66] Retamozo, S., Akasbi, M., Brito-Zeron, P., et al. Anti-Ro52 antibody testing influences the classification and clinical characterisation of primary Sjogren's syndrome. Clin Exp Rheumatol 30:5 (2012), 686–692.
67. [67] Hernandez-Molina, G., Leal-Alegre, G., Michel-Peregrina, M., The meaning of anti-Ro and anti-La antibodies in primary Sjogren's syndrome. Autoimmun Rev 10:3 (2011), 123–125.
68. [68] Theander, E., Jonsson, R., Sjostrom, B., et al. Prediction of Sjogren's Syndrome years before diagnosis and identification of patients with early onset and severe disease course by autoantibody profiling. Arthritis Rheumatol 67:9 (2015), 2427–2436.
69. [69] Davidson, B.K., Kelly, C.A., Griffiths, I.D., Primary Sjogren's syndrome in the North East of England: a long-term follow-up study. Rheumatol Oxf 38:3 (1999), 245–253.
70. [70] Casciola-Rosen, L.A., Anhalt, G., Rosen, A., Autoantigens targeted in systemic lupus erythematosus are clustered in two populations of surface structures on apoptotic keratinocytes. J Exp Med 179:4 (1994), 1317–1330.
71. [71] Reed, J.H., Jackson, M.W., Gordon, T.P., B cell apotopes of the 60-kDa Ro/SSA and La/SSB autoantigens. J Autoimmun 31:3 (2008), 263–267.
72. [72] Thurgood, L.A., Arentz, G., Lindop, R., et al. An immunodominant La/SSB autoantibody proteome derives from public clonotypes. Clin Exp Immunol 174:2 (2013), 237–244.
73. [73] Haneji, N., Nakamura, T., Takio, K., et al. Identification of alpha-fodrin as a candidate autoantigen in primary Sjogren's syndrome. Science 276:5312 (1997), 604–607.
74. [74] Hu, Q., Wang, D., Chen, W., The accuracy of the anti-alpha-fodrin antibody test for diagnosis of Sjogren's syndrome: a meta-analysis. Clin Biochem 46:15 (2013), 1372–1376.
75. [75] Shen, L., Suresh, L., Lindemann, M., et al. Novel autoantibodies in Sjogren's syndrome. Clin Immunol 145:3 (2012), 251–255.
76. [76] Bergum, B., Koro, C., Delaleu, N., et al. Antibodies against carbamylated proteins are present in primary Sjogren's syndrome and are associated with disease severity. Ann Rheum Dis, 2015 (Published Online First September 8 2015):annrheumdis-2015–207751.
77. Waterman, S.A., Gordon, T.P., Rischmueller, M., Inhibitory effects of muscarinic receptor autoantibodies on parasympathetic neurotransmission in Sjogren's syndrome. Arthritis Rheum 43:7 (2000), 1647–1654.
78. [78] Gordon, T.P., Bolstad, A.I., Rischmueller, M., et al. Autoantibodies in primary Sjogren's syndrome: new insights into mechanisms of autoantibody diversification and disease pathogenesis. Autoimmunity 34:2 (2001), 123–132.
79. [79] Roescher, N., Kingman, A., Shirota, Y., et al. Peptide-based ELISAs are not sensitive and specific enough to detect muscarinic receptor type 3 autoantibodies in serum from patients with Sjogren's syndrome. Ann Rheum Dis 70:1 (2011), 235–236.
80. [80] Bastian, I., Gordon, T.P., Jackson, M.W., A novel cell-based assay for inhibitory anti-muscarinic type 3 receptor antibodies in primary Sjogren's syndrome. J Immunol Methods 427 (2015), 117–121.
81. [81] Bournia, V.K., Vlachoyiannopoulos, P.G., Subgroups of Sjogren syndrome patients according to serological profiles. J Autoimmun 39:1–2 (2012), 15–26.
82. Vitali, C., Bombardieri, S., Jonsson, R., et al. Classification criteria for Sjogren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis 61:6 (2002), 554–558.
83. [83] Kyriakidis, N.C., Kapsogeorgou, E.K., Tzioufas, A.G., A comprehensive review of autoantibodies in primary Sjogren's syndrome: clinical phenotypes and regulatory mechanisms. J Autoimmun 51 (2014), 67–74.
84. [84] Fox, R., Pathogenesis of Sjogren's syndrome. 2015 November 2015. Waltham. MA: UpToDate.
85. [85] Cruz-Tapias, P., Rojas-Villarraga, A., Maier-Moore, S., Anaya, J.M., HLA and Sjogren's syndrome susceptibility. A meta-analysis of worldwide studies. Autoimmun Rev 11:4 (2012), 281–287.
86. [86] Bave, U., Nordmark, G., Lovgren, T., et al. Activation of the type I interferon system in primary Sjogren's syndrome: a possible etiopathogenic mechanism. Arthritis Rheum 52:4 (2005), 1185–1195.
87. [87] ter Borg, E.J., Risselada, A.P., Kelder, J.C., Relation of systemic autoantibodies to the number of extraglandular manifestations in primary Sjogren's Syndrome: a retrospective analysis of 65 patients in the Netherlands. Semin Arthritis Rheum 40:6 (2011), 547–551.
88. [88] Lessard, C.J., Li, H., Adrianto, I., et al. Variants at multiple loci implicated in both innate and adaptive immune responses are associated with Sjogren's syndrome. Nat Genet 45:11 (2013), 1284–1292.
89. [89] Li, Y., Zhang, K., Chen, H., et al. A genome-wide association study in Han Chinese identifies a susceptibility locus for primary Sjogren's syndrome at 7q11.23. Nat Genet 45:11 (2013), 1361–1365.
90. Liu, K., Kurien, B.T., Zimmerman, S.L., et al. X chromosome dose and sex bias in autoimmune diseases: increased 47,XXX in systemic lupus erythematosus and Sjogren's syndrome. Arthritis Rheumatol 68:5 (2016), 1290–1300.
91. [91] Kottyan, L.C., Zoller, E.E., Bene, J., et al. The IRF5-TNPO3 association with systemic lupus erythematosus has two components that other autoimmune disorders variably share. Hum Mol Genet 24:2 (2015), 582–596.
92. [92] Cornec, D., Jamin, C., Pers, J.O., Sjogren's syndrome: where do we stand, and where shall we go?. J Autoimmun 51 (2014), 109–114.
93. [93] Hall, J.C., Baer, A.N., Shah, A.A., et al. Molecular subsetting of interferon pathways in Sjogren's syndrome. Arthritis Rheumatol 67:9 (2015), 2437–2446.
94. [94] Mackay, F., Sierro, F., Grey, S.T., et al. The BAFF/APRIL system: an important player in systemic rheumatic diseases. Curr Dir Autoimmun 8 (2005), 243–265.
95. [95] Mackay, F., Groom, J., Tangye, S., An important role for B-cell activation factor and B cells in the pathogenesis of Sjogren's Syndrome. Curr Opin Rheumatol 19:5 (2007), 406–413.
96. [96] Vitali, C., Bombardieri, S., Moutsopoulos, H.M., et al. Preliminary criteria for the classification of Sjogren's syndrome. Results of a prospective concerted action supported by the European Community. Arthritis Rheum 36:3 (1993), 340–347.
97. [97] Whitcher, J.P., Shiboski, C.H., Shiboski, S.C., et al. A simplified quantitative method for assessing keratoconjunctivitis sicca from the Sjogren's Syndrome International Registry. Am J Ophthalmol 149:3 (2010), 405–415.
98. [98] Rasmussen, A., Ice, J.A., Li, H., et al. Comparison of the American-European Consensus Group Sjogren's syndrome classification criteria to newly proposed American College of Rheumatology criteria in a large, carefully characterised sicca cohort. Ann Rheum Dis 73:1 (2014), 31–38.
99. [99] Bowman, S.J., Fox, R.I., Classification criteria for Sjogren's syndrome: nothing ever stands still!. Ann Rheum Dis 73:1 (2014), 1–2.
100. [100] Gordon, P., Khamashta, M.A., Rosenthal, E., et al. Anti-52 kDa Ro, anti-60 kDa Ro, and anti-La antibody profiles in neonatal lupus. J Rheumatol 31:12 (2004), 2480–2487.
101. [101] Keech, C.L., Howarth, S., Coates, T., et al. Rapid and sensitive detection of anti-Ro (SS-A) antibodies by indirect immunofluorescence of 60kDa Ro HEp-2 transfectants. Pathology 28:1 (1996), 54–57.
102. [102] Carubbi, F., Alunno, A., Cipriani, P., et al. A retrospective, multicenter study evaluating the prognostic value of minor salivary gland histology in a large cohort of patients with primary Sjogren's syndrome. Lupus 24:3 (2015), 315–320.
103. [103] Daniels, T.E., Labial salivary gland biopsy in Sjogren's syndrome. Assessment as a diagnostic criterion in 362 suspected cases. Arthritis Rheum 27:2 (1984), 147–156.
104. [104] Daniels, T.E., Cox, D., Shiboski, C.H., et al. Associations between salivary gland histopathologic diagnoses and phenotypic features of Sjogren's syndrome among 1,726 registry participants. Arthritis Rheum 63:7 (2011), 2021–2030.
105. [105] Costa, S., Quintin-Roue, I., Lesourd, A., et al. Reliability of histopathological salivary gland biopsy assessment in Sjogren's syndrome: a multicentre cohort study. Rheumatol Oxf 54:6 (2015), 1056–1064.
106. [106] Cornec, D., Jousse-Joulin, S., Saraux, A., Devauchelle-Pensec, V., Salivary gland ultrasound to diagnose Sjogren's syndrome: a claim to standardize the procedure. Rheumatol Oxf 54:1 (2015), 199–200.
107. [107] Gabbriellini, G., Baldini, C., Varanini, V., et al. In vivo confocal scanning laser microscopy in patients with primary Sjogren's syndrome: a monocentric experience. Mod Rheumatol 25:4 (2015), 585–589.
108. [108] Chen, W., Cao, H., Lin, J., et al. Biomarkers for primary Sjogren's syndrome. Genomics Proteomics Bioinforma 13:4 (2015), 219–223.
109. [109] Seror, R., Theander, E., Brun, J.G., et al. Validation of EULAR primary Sjogren's syndrome disease activity (ESSDAI) and patient indexes (ESSPRI). Ann Rheum Dis 74:5 (2015), 859–866.
110. [110] Seror, R., Ravaud, P., Mariette, Z., et al. EULAR Sjogren's Syndrome Patient Reported Index (ESSPRI): development of a consensus patient index for primary Sjogren's syndrome. Ann Rheum Dis 70 (2011), 968–972.
111. [111] Lendrem, D., Mitchell, S., McMeekin, P., et al. Health-related utility values of patients with primary Sjogren's syndrome and its predictors. Ann Rheum Dis 73 (2013), 1362–1368.
112. [112] Meiners, P.M., Arends, S., Brouwer, E., et al. Responsiveness of disease activity indices ESSPRI and ESSDAI in patients with primary Sjogren's syndrome treated with rituximab. Ann Rheum Dis 71 (2012), 1297–1302.
113. [113] Seror, R., Mariette, X., Bowman, S., et al. Accurate detection of changes in disease activity in primary Sjogren's syndrome by the European League against rheumatism Sjogren's syndrome disease activity index. Arthritis Care Res Hob 62:4 (2010), 551–558.
114. [114] Seror, R., Meiners, P., Baron, G., et al. Development of the ClinESSDAI: a clinical score without biological domain. A tool for biological studies. Ann Rheum Dis, 2016 (In Press).
115. [115] Seror, R., Bootsma, H., Saraux, A., et al. Defining disease activity states and clinically meaningful improvement in primary Sjogren's syndrome with EULAR primary Sjogren's syndrome disease activity (ESSDAI) and patient-reported indexes (ESSPRI). Ann Rheum Dis 75:2 (2016), 382–389.
116. [116] Cornec, D., Devauchelle-Pensec, V., Mariette, X., et al. Development of the Sjogren's Syndrome Responder Index, a data-driven composite endpoint for assessing treatment efficacy. Rheumatol Oxf 54:9 (2015), 1699–1708.
117. [117] Vitali, C., Palombi, G., Baldini, C., et al. Sjogren's Syndrome Disease Damage Index and disease activity index: scoring systems for the assessment of disease damage and disease activity in Sjogren's syndrome, derived from an analysis of a cohort of Italian patients. Arthritis Rheum 56:7 (2007), 2223–2231.
118. [118] Barry, R.J., Sutcliffe, N., Isenberg, D.A., et al. The Sjogren's Syndrome Damage Index–a damage index for use in clinical trials and observational studies in primary Sjogren's syndrome. Rheumatol Oxf 47:8 (2008), 1193–1198.
119. Foulks, G.N., Forstot, S.L., Donshik, P.C., et al. Clinical guidelines for management of dry eye associated with Sjogren disease. Ocul Surf 13:2 (2015), 118–132.
120. [120] Barber, L.D., Pflugfelder, S.C., Tauber, J., et al. Phase III safety evaluation of cyclosporine 0.1% ophthalmic emulsion administered twice daily to dry eye disease patients for up to 3 years. Ophthalmology 112:10 (2005), 1790–1794.
121. [121] Kojima, T., Ishida, R., Dogru, M., et al. The effect of autologous serum eyedrops in the treatment of severe dry eye disease: a prospective randomized case-control study. Am J Ophthalmol 139:2 (2005), 242–246.
122. [122] Ben Gaddie, I., Whet your appetite for new dry eye drugs. Rev Optometry 152:5 (2015), 61–65.
123. Gonzalez, S., Sung, H., Sepulveda, D., et al. Oral manifestations and their treatment in Sjogren's syndrome. Oral Dis 20:2 (2014), 153–161.
124. [124] Furness, S., Worthington, H.V., Bryan, G., et al. Interventions for the management of dry mouth: topical therapies. Cochrane Database Syst Rev, 7(12), 2011, CD008934.
125. [125] Vivino, F.B., Al-Hashimi, I., Khan, Z., et al. Pilocarpine tablets for the treatment of dry mouth and dry eye symptoms in patients with Sjogren syndrome: a randomized, placebo-controlled, fixed-dose, multicenter trial. P92-01 Study Group. Arch Intern Med 159:2 (1999), 174–181.
126. [126] Fife, R.S., Chase, W.F., Dore, R.K., et al. Cevimeline for the treatment of xerostomia in patients with Sjogren syndrome: a randomized trial. Arch Intern Med 162:11 (2002), 1293–1300.
127. [127] Tan, J., Rischmueller, M., Sjögren's syndrome in 2013. Med Today 14:6 (2013), 26–35.
128. [128] Gottenberg, J.E., Ravaud, P., Puechal, X., et al. Effects of hydroxychloroquine on symptomatic improvement in primary Sjogren syndrome: the JOQUER randomized clinical trial. JAMA 312:3 (2014), 249–258.
129. [129] Skopouli, F.N., Jagiello, P., Tsifetaki, N., Moutsopoulos, H.M., Methotrexate in primary Sjogren's syndrome. Clin Exp Rheumatol 14:5 (1996), 555–558.
130. [130] Ramos-Casals, M., Tzioufas, A.G., Stone, J.H., et al. Treatment of primary Sjogren syndrome: a systematic review. JAMA 304:4 (2010), 452–460.
131. [131] Gottenberg, J.E., Cinquetti, G., Larroche, C., et al. Efficacy of rituximab in systemic manifestations of primary Sjogren's syndrome: results in 78 patients of the AutoImmune and Rituximab registry. Ann Rheum Dis 72:6 (2013), 1026–1031.
132. [132] Carubbi, F., Alunno, A., Cipriani, P., et al. Rituximab in primary Sjogren's syndrome: a ten-year journey. Lupus 23:13 (2014), 1337–1349.
133. [133] Meijer, J.M., Meiners, P.M., Vissink, A., et al. Effectiveness of rituximab treatment in primary Sjogren's syndrome: a randomized, double-blind, placebo-controlled trial. Arthritis Rheum 62:4 (2010), 960–968.
134. [134] Devauchelle-Pensec, V., Mariette, X., Jousse-Joulin, S., et al. Treatment of primary Sjogren syndrome with rituximab: a randomized trial. Ann Intern Med 160:4 (2014), 233–242.
135. [135] St Clair, E.W., Levesque, M.C., Prak, E.T., et al. Rituximab therapy for primary Sjogren's syndrome: an open-label clinical trial and mechanistic analysis. Arthritis Rheum 65:4 (2013), 1097–1106.
136. [136] Mariette, X., Seror, R., Quartuccio, L., et al. Efficacy and safety of belimumab in primary Sjogren's syndrome: results of the BELISS open-label phase II study. Ann Rheum Dis 74:3 (2015), 526–531.
137. [137] Meiners, P.M., Vissink, A., Kroese, F.G., et al. Abatacept treatment reduces disease activity in early primary Sjogren's syndrome (open-label proof of concept ASAP study). Ann Rheum Dis 73:7 (2014), 1393–1396.
138. [138] Cornec, D., Saraux, A., Devauchelle-Pensec, V., et al. The future of B cell-targeted therapies in Sjogren's syndrome. Immunotherapy 5:6 (2013), 639–646.
139. [139] Gottenberg, J.E., Mariette, X., Primary Sjogren's syndrome: time for prospective cohorts. Curr Pharm Biotechnol 13:10 (2012), 2022–2025.
140. [140] Ng, W.F., Bowman, S.J., Griffiths, B., Group Us, United Kingdom Primary Sjogren's Syndrome Registry–a united effort to tackle an orphan rheumatic disease. Rheumatol Oxf 50:1 (2011), 32–39.
141. [141] Gottenberg, J.E., Seror, R., Miceli-Richard, C., et al. Serum levels of beta2-microglobulin and free light chains of immunoglobulins are associated with systemic disease activity in primary Sjogren's syndrome. Data at enrollment in the prospective ASSESS cohort. PLoS One, 8(5), 2013, e59868.